Vicore Pharma Announces Presentations at the European Respiratory Society (ERS) International Congress 2023
Stockholm, September 6, 2023 – Vicore Pharma Holding AB (publ), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), announced today that it will present two posters on its lead program, C21, under development for the treatment of idiopathic pulmonary fibrosis (IPF), at the European Respiratory Society (ERS) International Congress 2023 in Milan, Italy September 9-13.